Perkins Adelene Q 4
4 · INFINITY PHARMACEUTICALS, INC. · Filed Sep 12, 2023
Insider Transaction Report
Form 4
Perkins Adelene Q
Pres & Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2023-09-09+768,133→ 1,585,487 total - Sale
Common Stock
2023-09-12$0.07/sh−410,196$28,714→ 1,175,291 total - Exercise/Conversion
Restricted Stock Unit
2023-09-09−768,133→ 0 total→ Common Stock (768,133 underlying)
Holdings
- 16,446.795(indirect: By 401(k))
Common Stock
Footnotes (3)
- [F1]Restricted stock units ("RSUs") convert into Common Stock of the issuer on a one-for-one basis. This transaction represents the settlement of RSUs in shares of Common Stock on their vesting date.
- [F2]Pursuant to a binding contract entered into between the issuer and the reporting person on August 15, 2022, this represents the shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the RSUs listed in Table II. Such binding contract is intended to be consistent with the affirmative action defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. This sale does not represent a discretionary trade by the reporting person.
- [F3]On August 11, 2022, the reporting person was granted RSUs, of which all 768,133 vested as of September 9, 2023.